Q3 Revenue Climbs 8% to $207.6M as BAQSIMI and Primatene Hit Records
AMPH sits 66% above its 52-week low of $16.645.
Summary
Amphastar posted Q3 net revenue of $207.6 million, up 8% from $191.8 million a year ago, with record BAQSIMI ($58.8 million, +10%) and Primatene MIST ($31.5 million, +9%) sales plus $6.6 million from newly launched ipratropium bromide. GAAP net income more than doubled to $37.8 million, or $0.87 per diluted share, though the prior-year quarter carried a $23.1 million litigation provision that flattered the comparison; adjusted non-GAAP EPS rose to $1.14 from $0.93. Gross margin compressed to 48.0% from 51.4% on lower BAQSIMI and glucagon pricing and higher IMS remediation and plant expansion costs, and glucagon revenue fell 37% on competition while epinephrine slipped 19% on slower releases tied to the FDA warning letter at IMS. The board added $50 million to the buyback on November 4, aimed at offsetting equity-compensation dilution. The quarter shows the top line holding up on new launches, but margin pressure and the IMS remediation remain the swing factors.
At the time of this announcement, AMPH was trading at $27.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.